Free Trial

Cadrenal Therapeutics (CVKD) Competitors

Cadrenal Therapeutics logo
$14.75 -0.28 (-1.86%)
As of 02:32 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CVKD vs. COYA, SGMT, IVVD, MGNX, BDTX, CTNM, ENTX, KYTX, OPTN, and HLVX

Should you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Coya Therapeutics (COYA), Sagimet Biosciences (SGMT), Invivyd (IVVD), MacroGenics (MGNX), Black Diamond Therapeutics (BDTX), Contineum Therapeutics (CTNM), Entera Bio (ENTX), Kyverna Therapeutics (KYTX), OptiNose (OPTN), and HilleVax (HLVX). These companies are all part of the "pharmaceutical products" industry.

Cadrenal Therapeutics vs.

Coya Therapeutics (NASDAQ:COYA) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, community ranking, risk and media sentiment.

Coya Therapeutics' return on equity of -31.63% beat Cadrenal Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Coya TherapeuticsN/A -31.63% -27.76%
Cadrenal Therapeutics N/A -142.95%-118.40%

Coya Therapeutics received 19 more outperform votes than Cadrenal Therapeutics when rated by MarketBeat users. Likewise, 92.86% of users gave Coya Therapeutics an outperform vote while only 87.50% of users gave Cadrenal Therapeutics an outperform vote.

CompanyUnderperformOutperform
Coya TherapeuticsOutperform Votes
26
92.86%
Underperform Votes
2
7.14%
Cadrenal TherapeuticsOutperform Votes
7
87.50%
Underperform Votes
1
12.50%

Coya Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.

Coya Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 193.86%. Cadrenal Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 117.61%. Given Coya Therapeutics' higher probable upside, equities research analysts clearly believe Coya Therapeutics is more favorable than Cadrenal Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coya Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cadrenal Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Coya Therapeutics has higher revenue and earnings than Cadrenal Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coya Therapeutics$3.69M26.26-$7.99M-$1.07-5.41
Cadrenal TherapeuticsN/AN/A-$8.36M-$9.26-1.59

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 9.8% of Coya Therapeutics shares are owned by insiders. Comparatively, 48.6% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Coya Therapeutics had 14 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 19 mentions for Coya Therapeutics and 5 mentions for Cadrenal Therapeutics. Coya Therapeutics' average media sentiment score of 0.53 beat Cadrenal Therapeutics' score of -0.20 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Coya Therapeutics
2 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Cadrenal Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Coya Therapeutics beats Cadrenal Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Cadrenal Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CVKD vs. The Competition

MetricCadrenal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$28.93M$6.47B$5.31B$8.31B
Dividend YieldN/A2.64%5.20%4.10%
P/E Ratio-2.208.5926.6919.58
Price / SalesN/A257.78393.58120.51
Price / CashN/A65.8538.2534.62
Price / Book1.666.396.744.47
Net Income-$8.36M$143.98M$3.23B$248.32M
7 Day Performance-5.13%-0.06%0.01%-1.26%
1 Month Performance-12.89%1.64%8.69%10.52%
1 Year PerformanceN/A-0.73%18.36%8.53%

Cadrenal Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CVKD
Cadrenal Therapeutics
2.7764 of 5 stars
$14.75
-1.9%
$32.00
+116.9%
N/A$29.01MN/A-2.214News Coverage
Analyst Revision
COYA
Coya Therapeutics
2.09 of 5 stars
$6.14
+1.5%
$17.00
+176.9%
-29.6%$102.69M$3.55M-9.456Analyst Downgrade
Analyst Revision
SGMT
Sagimet Biosciences
1.5615 of 5 stars
$3.31
+1.5%
$22.40
+576.7%
-32.9%$101.53M$2M-2.318Gap Down
IVVD
Invivyd
2.8972 of 5 stars
$0.84
+29.7%
$7.52
+797.2%
-64.8%$100.50M$25.38M-0.43100Gap Up
MGNX
MacroGenics
3.6681 of 5 stars
$1.59
+11.2%
$7.43
+367.2%
-66.4%$100.31M$148.34M-1.01430News Coverage
Analyst Forecast
Analyst Revision
BDTX
Black Diamond Therapeutics
3.1684 of 5 stars
$1.75
+6.7%
$14.60
+734.3%
-59.1%$99.19MN/A-1.3290News Coverage
Positive News
Analyst Upgrade
Gap Up
CTNM
Contineum Therapeutics
2.4087 of 5 stars
$3.83
-1.0%
$23.75
+520.1%
-75.3%$99.09M$50M-0.7831
ENTX
Entera Bio
1.9571 of 5 stars
$2.15
flat
$10.00
+365.1%
-17.3%$97.66M$181,000.00-8.2720News Coverage
Positive News
Gap Up
KYTX
Kyverna Therapeutics
2.1768 of 5 stars
$2.21
+4.7%
$18.33
+729.6%
-81.5%$95.51M$7.03M-0.6496News Coverage
Analyst Revision
Gap Up
OPTN
OptiNose
3.1658 of 5 stars
$9.42
+0.3%
$9.00
-4.5%
N/A$95.09M$78.23M-2.24190News Coverage
Analyst Revision
HLVX
HilleVax
2.4114 of 5 stars
$1.89
-0.5%
$3.00
+58.7%
-86.8%$94.77MN/A-0.6120News Coverage

Related Companies and Tools


This page (NASDAQ:CVKD) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners